Advertisement

Psychopharmacology

, Volume 235, Issue 3, pp 651–661 | Cite as

Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood

  • Britta HahnEmail author
  • Carolyn H. Reneski
  • Ana Pocivavsek
  • Robert Schwarcz
Original Investigation

Abstract

Rationale

Elevated brain kynurenic acid (KYNA) levels are implicated in the pathology and neurodevelopmental pathogenesis of schizophrenia. In rats, embryonic treatment with kynurenine (EKyn) causes elevated brain KYNA levels in adulthood and cognitive deficits reminiscent of schizophrenia.

Objectives

Growing evidence suggests that people with schizophrenia have a narrowed attentional focus, and we aimed at establishing whether these abnormalities may be related to KYNA dysregulation.

Methods

To test whether EKyn rats display broad monitoring deficits, kynurenine was added to the chow of pregnant Wistar dams on embryonic days 15–22. As adults, 20 EKyn and 20 control rats were trained to stable performance on the five-choice serial reaction time task, requiring the localization of 1-s light stimuli presented randomly across five apertures horizontally arranged along a curved wall, equating the locomotor demands of reaching each hole.

Results

EKyn rats displayed elevated omission errors and reduced anticipatory responses relative to control rats, indicative of a lower response rate, and showed reduced locomotor activity. The ability to spread attention broadly was measured by parsing performance by stimulus location. Both groups displayed poorer stimulus detection with greater target location eccentricity, but this effect was significantly more pronounced in the EKyn group. Specifically, the groups differed in the spatial distribution of correct but not incorrect responses. This pattern cannot be explained by differences in response rate and is indicative of a narrowed attentional focus.

Conclusions

The findings suggest a potential etiology of broad monitoring deficits in schizophrenia, which may constitute a core cognitive deficit.

Keywords

Kynurenic acid Prenatal Attention Broad monitoring 5-Choice serial reaction time 

Notes

Acknowledgements

This work was supported by a Silvio O. Conte Center grant (P50 MH103222) and R01 DA035813 (B. Hahn). A. Pocivavsek is a trainee on K12 HD43489-14. We thank Ashleigh Wells and Taylor Radden for contributing to data collection.

Funding information

This work was supported by a Silvio O. Conte Center grant (P50 MH103222) and R01 DA035813 (B. Hahn). A. Pocivavsek is a trainee on K12 HD43489-14.

Compliance with ethical standards

Conflict of interest

Britta Hahn, Carolyn Reneski, Ana Pocivavsek, and Robert Schwarcz declare that they have no conflict of interest.

Human and animal rights and informed consent

The treatment of animals followed the “Principles of Laboratory Animal Care” (NIH publication No. 86-23, 1996) and was approved by the Institutional Animal Care and Use Committee of the University of Maryland School of Medicine.

References

  1. Akagbosu CO, Evans GC, Gulick D, Suckow RF, Bucci DJ (2012) Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. Schizophr Bull 38:769–778CrossRefPubMedGoogle Scholar
  2. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89:73–120CrossRefPubMedPubMedCentralGoogle Scholar
  3. Alexander KS, Wu HQ, Schwarcz R, Bruno JP (2012) Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology 220:627–637CrossRefPubMedGoogle Scholar
  4. Alexander KS, Pocivavsek A, HQ W, Pershing ML, Schwarcz R, Bruno JP (2013) Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine. Neuroscience 238:19–28CrossRefPubMedPubMedCentralGoogle Scholar
  5. Amitai N, Markou A (2009) Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment. Pharmacol Biochem Behav 93:248–257CrossRefPubMedGoogle Scholar
  6. Bagasrawala I, Zecevic N, Radonjic NV (2016) N-methyl d-aspartate receptor antagonist kynurenic acid affects human cortical development. Front Neurosci 10:435CrossRefPubMedPubMedCentralGoogle Scholar
  7. Balu DT, Coyle JT (2015) The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond. Curr Opin Pharmacol 20:109–115CrossRefPubMedGoogle Scholar
  8. Barnes SA, Sawiak SJ, Caprioli D, Jupp B, Buonincontri G, Mar AC, Harte MK, Fletcher PC, Robbins TW, Neill JC, Dalley JW (2014) Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia. Int J Neuropsychopharmacol 18Google Scholar
  9. Chess AC, Simoni MK, Alling TE, Bucci DJ (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 33:797–804CrossRefPubMedGoogle Scholar
  10. Chess AC, Landers AM, Bucci DJ (2009) L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav Brain Res 201:325–331CrossRefPubMedGoogle Scholar
  11. DeAngeli NE, Todd TP, Chang SE, Yeh HH, Yeh PW, Bucci DJ (2014) Exposure to kynurenic acid during adolescence increases sign-tracking and impairs long-term potentiation in adulthood. Front Behav Neurosci 8:451PubMedGoogle Scholar
  12. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G (2001) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313:96–98CrossRefPubMedGoogle Scholar
  13. Erhardt S, Schwieler L, Emanuelsson C, Geyer M (2004) Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 56:255–260CrossRefPubMedGoogle Scholar
  14. Erhardt S, Schwieler L, Imbeault S, Engberg G (2017) The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology 112:297–306CrossRefPubMedGoogle Scholar
  15. Fatemi SH, Folsom TD (2009) The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 35:528–548CrossRefPubMedPubMedCentralGoogle Scholar
  16. Featherstone RE, Rizos Z, Nobrega JN, Kapur S, Fletcher PJ (2007) Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology 32:483–492CrossRefPubMedGoogle Scholar
  17. Forrest CM, McNair K, Pisar M, Khalil OS, Darlington LG, Stone TW (2015) Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine. Neuroscience 310:91–105CrossRefPubMedPubMedCentralGoogle Scholar
  18. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007–2017CrossRefPubMedGoogle Scholar
  19. Gold JM, Hahn B, Strauss GP, Waltz JA (2009) Turning it upside down: areas of preserved cognitive function in schizophrenia. Neuropsychol Rev 19:294–311CrossRefPubMedPubMedCentralGoogle Scholar
  20. Gray BE, Hahn B, Robinson B, Harvey A, Leonard CJ, Luck SJ, Gold JM (2014) Relationships between divided attention and working memory impairment in people with schizophrenia. Schizophr Bull 40:1462–1471CrossRefPubMedPubMedCentralGoogle Scholar
  21. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321–330CrossRefPubMedGoogle Scholar
  22. Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72:41–51CrossRefPubMedGoogle Scholar
  23. Hahn B, Shoaib M, Stolerman IP (2002) Nicotine-induced enhancement of attention in the five-choice serial reaction time task: the influence of task demands. Psychopharmacology 162:129–137CrossRefPubMedGoogle Scholar
  24. Hahn B, Hollingworth A, Robinson BM, Kaiser ST, Leonard CJ, Beck VM, Kappenman ES, Luck SJ, Gold JM (2012a) Control of working memory content in schizophrenia. Schizophr Res 134:70–75CrossRefPubMedGoogle Scholar
  25. Hahn B, Robinson BM, Harvey AN, Kaiser ST, Leonard CJ, Luck SJ, Gold JM (2012b) Visuospatial attention in schizophrenia: deficits in broad monitoring. J Abnorm Psychol 121:119–128CrossRefPubMedGoogle Scholar
  26. Hahn B, Harvey AN, Concheiro-Guisan M, Huestis MA, Holcomb HH, Gold JM (2013) A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol Psychiatry 74:436–443CrossRefPubMedPubMedCentralGoogle Scholar
  27. Hahn B, Harvey AN, Gold JM, Fischer BA, Keller WR, Ross TJ, Stein EA (2016) Hyperdeactivation of the default mode network in people with schizophrenia when focusing attention in space. Schizophr Bull 42:1158–1166CrossRefPubMedPubMedCentralGoogle Scholar
  28. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463–7473PubMedGoogle Scholar
  29. Holtze M, Saetre P, Engberg G, Schwieler L, Werge T, Andreassen OA, Hall H, Terenius L, Agartz I, Jonsson EG, Schalling M, Erhardt S (2012) Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. J Psychiatry Neurosci 37:53–57CrossRefPubMedPubMedCentralGoogle Scholar
  30. Iaccarino HF, Suckow RF, Xie S, Bucci DJ (2013) The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: implications for schizophrenia. Schizophr Res 150:392–397CrossRefPubMedGoogle Scholar
  31. Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319–1328CrossRefPubMedGoogle Scholar
  32. Kiank C, Zeden JP, Drude S, Domanska G, Fusch G, Otten W, Schuett C (2010) Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans. PLoS One 5:e11825CrossRefPubMedPubMedCentralGoogle Scholar
  33. Kreither J, Lopez-Calderon J, Leonard CJ, Robinson BM, Ruffle A, Hahn B, Gold JM, Luck SJ (2017) Electrophysiological evidence for hyperfocusing of spatial attention in schizophrenia. J Neurosci 37:3813–3823CrossRefPubMedPubMedCentralGoogle Scholar
  34. Leonard CJ, Kaiser ST, Robinson BM, Kappenman ES, Hahn B, Gold JM, Luck SJ (2013) Toward the neural mechanisms of reduced working memory capacity in schizophrenia. Cereb Cortex 23:1582–1592CrossRefPubMedGoogle Scholar
  35. Lewis DA, Levitt P (2002) Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25:409–432CrossRefPubMedGoogle Scholar
  36. Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, Samuelsson M, Erhardt S (2012) Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 38:426–432CrossRefPubMedGoogle Scholar
  37. Luck SJ, McClenon C, Beck VM, Hollingworth A, Leonard CJ, Hahn B, Robinson BM, Gold JM (2014) Hyperfocusing in schizophrenia: evidence from interactions between working memory and eye movements. J Abnorm Psychol 123:783–795CrossRefPubMedPubMedCentralGoogle Scholar
  38. MacDonald JF, Jackson MF, Beazely MA (2006) Hippocampal long-term synaptic plasticity and signal amplification of NMDA receptors. Crit Rev Neurobiol 18:71–84CrossRefPubMedGoogle Scholar
  39. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S (2004) Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 15:618–629CrossRefPubMedGoogle Scholar
  40. Miller CL, Llenos IC, Dulay JR, Weis S (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1073-1074:25–37CrossRefPubMedGoogle Scholar
  41. Mirza NR, Stolerman IP (1998) Nicotine enhances sustained attention in the rat under specific task conditions. Psychopharmacology 138:266–274CrossRefPubMedGoogle Scholar
  42. Muller N, Schwarz M (2006) Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 10:131–148CrossRefPubMedGoogle Scholar
  43. Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstrom LH, Nordin C, Karanti A, Persson P, Erhardt S (2005) Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 80:315–322CrossRefPubMedGoogle Scholar
  44. Nilsson LK, Linderholm KR, Erhardt S (2006) Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons. J Neural Transm (Vienna) 113:557–571CrossRefGoogle Scholar
  45. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004) Identification of separable cognitive factors in schizophrenia. Schizophr Res 72:29–39CrossRefPubMedGoogle Scholar
  46. Paine TA, Carlezon WA Jr (2009) Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats. Neuropharmacology 56:788–797CrossRefPubMedPubMedCentralGoogle Scholar
  47. Pershing ML, Bortz DM, Pocivavsek A, Fredericks PJ, Jorgensen CV, Vunck SA, Leuner B, Schwarcz R, Bruno JP (2015) Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia. Neuropharmacology 90:33–41CrossRefPubMedGoogle Scholar
  48. Pershing ML, Phenis D, Valentini V, Pocivavsek A, Lindquist DH, Schwarcz R, Bruno JP (2016) Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding. Psychopharmacology 233:3725–3735CrossRefPubMedPubMedCentralGoogle Scholar
  49. Pocivavsek A, HQ W, Elmer GI, Bruno JP, Schwarcz R (2012) Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci 35:1605–1612CrossRefPubMedPubMedCentralGoogle Scholar
  50. Pocivavsek A, Thomas MA, Elmer GI, Bruno JP, Schwarcz R (2014) Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. Psychopharmacology 231:2799–2809CrossRefPubMedPubMedCentralGoogle Scholar
  51. Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, Schwarcz R (2011) Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 37:1147–1156CrossRefPubMedGoogle Scholar
  52. Sawaki R, Kreither J, Leonard CJ, Kaiser ST, Hahn B, Gold JM, Luck SJ (2017) Hyperfocusing of attention on goal-related information in schizophrenia: evidence from electrophysiology. J Abnorm Psychol 126:106–116CrossRefPubMedGoogle Scholar
  53. Schwarcz R, Rassoulpour A, HQ W, Medoff D, Tamminga CA, Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521–530CrossRefPubMedGoogle Scholar
  54. Schwarcz R, Bruno JP, Muchowski PJ, HQ W (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13:465–477CrossRefPubMedPubMedCentralGoogle Scholar
  55. Shepard PD, Joy B, Clerkin L, Schwarcz R (2003) Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28:1454–1462CrossRefPubMedGoogle Scholar
  56. Trecartin KV, Bucci DJ (2011) Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats. Schizophr Res 133:156–158CrossRefPubMedPubMedCentralGoogle Scholar
  57. Widner B, Ledochowski M, Fuchs D (2000) Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences. Curr Drug Metab 1:193–204CrossRefPubMedGoogle Scholar
  58. Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE, Kajii Y, Thaker GK, Schwarcz R (2011) Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 68:665–674CrossRefPubMedGoogle Scholar
  59. Young JW, Geyer MA (2013) Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol 86:1122–1132CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • Britta Hahn
    • 1
    Email author
  • Carolyn H. Reneski
    • 1
  • Ana Pocivavsek
    • 1
  • Robert Schwarcz
    • 1
  1. 1.Maryland Psychiatric Research CenterUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations